Comparative Expression Analysis of Somatostatin Receptor Subtypes in Human Neuroendocrine Tumors Using Two Sets of New Monoclonal Antibodies Abstract #446

Introduction: Expression of somatostatin receptor subtypes (sstr) is required for the successful use of somatostatin analogues (SSA) in the treatment of neuroendocrine tumors (NET). Reliable detection of sstr could improve the selection of SSA treatment. Rabbit and mouse monoclonal antibodies (mAbs) were recently developed independently in Jena and Basel.
Aim(s): To evaluate the utility of two sets of mAbs against sstr1, 2, 3, 5 in formaldehyde-fixed NETs.
Materials and methods: Newly generated mouse and rabbit mAbs specific to human sstr1, 2, 3, 5 were characterized with transfected HEK293 cells and normal pancreatic tissue. Comparative analysis of rabbit v. mouse mAbs was also conducted by immunostaining a tissue microarray (TMA) of 75 NET cores. Scoring was done with image analysis algorithms (Aperio).
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Herbert Schmid

To read results and conclusion, please login ...

Further abstracts you may be interested in

#302 Monoclonal Antibodies Against the Human Somatostatin Receptor Subtypes 1-5: Characterization and Immunohistochemical Application in Gastrointestinal Neuroendocrine Tumors
Introduction: A lack of well-characterized somatostatin receptor (sstr)-specific antibodies has hampered development of routine sstr expression profiles that may be useful in the treatment of NET patients (pts).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Chiara Lambertini
#2854 A Meta-Analysis of the Accuracy of a Neuroendocrine Tumor mRNA Genomic Biomarker (NETest) in Blood
Introduction: The lack of an accurate blood biomarker in neuroendocrine tumor (NET) disease impedes effective management.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: MD, PhD Lisa Bodei
#2894 Single Institution Experience with Peptide Receptor Radionuclide Therapy (PRRT) in Neuroendocrine Tumors (NET)
Introduction: Neuroendocrine tumors (NETs) are a rare and heterogenous group of tumors with rising incidence. Peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogue is an encouraging systemic treatment modality with minimum side effects.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr. Heying Duan
Authors: Duan H, Ninatti G, Girod B, Ferri V, ...
Keywords: NET, PRRT, ORR, PFS
#2985 Peptide Receptor Radionuclide Therapy (PRRT) Outcome Prediction in Neuroendocrine Tumors (NET): Could Radiomic Features Analysis of 68Ga-DOTATOC PET/CT Have a Roll?
Introduction: The PRRT is an effective treatment for NET, but the selection of a good candidate is a very important step.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Virginia Liberini
#2981 The Distance from Pathology to Molecular Imaging: SSTR Expression Comparison in 100 Gastroenteropancreatic Neuroendocrine Neoplasms
Introduction: Somatostatin receptor (SSTR) overexpression is a unique feature of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs), which establish the basis for both diagnosis and therapy. SSTR status can be evaluated by immunohistochemical staining (IHC) and 68Ga-DOTATATE PET/CT.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Pathology - grading, staging
Presenting Author: Jiangyuan Yu
Authors: Yu J, Cao F, Yang Z, Sun Y, ...
Keywords: GEP-NEN, SSTR, PET/CT, IHC